For the Culture By The Culture. ISSN: 3064-9331.
Ohio rewrites its legalization law before it even starts, Wisconsin offers fake reform, and Massachusetts keeps spinning its regulatory wheels. The FDA pretends to act on CBD while the European Union adds new walls around its market. Reefer Report Card Vol. 20 grades another week of confusion, contradiction, and missed opportunities in global cannabis reform.
A German biotech is pushing a cannabis pill called VER 01 and calling it a breakthrough for pain relief. Beneath the pharmaceutical polish is a deeper story about control, money, and culture. Pot Culture Magazine asks if Vertanical’s lab born weed is progress or just another corporate grab for the plant the people built.
The Netherlands is finally confronting its cannabis hypocrisy. After decades of letting coffee shops sell weed sourced from the black market, the Dutch government is expanding a state-run program that licenses legal growers. The plan could eliminate contamination, crush the illicit trade, and restore integrity to the nation that once sold the world on tolerance but never practiced it.
A hundred years after the 1925 International Opium Convention first outlawed cannabis, prohibition still stands as one of the biggest policy failures in modern history. From colonial fear and racist propaganda to Nixon’s drug war and global treaties, the cost has been human lives, stolen freedom, and wasted truth. The plant survived. The lies didn’t.
This week’s cannabis report card runs the gamut: Ohio hits $3B in sales while federal reform stays stuck, Connecticut raids smoke shops, and California wipes out 21,000 plants in public land raids. The lone bright spot comes from Thailand, where the new Prime Minister pledged support for reform. One win, too many failures.
Reefer Report Card Vol. 14 grades the week in weed. Texas killed its hemp ban but raised the age gate, New York’s equity rules collapsed in court, Ohio towns stalled legalization, Nebraska strangled patients before launch, and Thailand’s new PM carries a cannabis legacy without clear promises.
